|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1050 K STREET, NW, #800 |
Address2 | |
| City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | RESEARCH TRIANGLE PARK |
State | NC |
Zip Code | 27709 |
Country | USA |
|
5. Senate ID# 16293-12
|
||||||||
|
6. House ID# 314610000
|
||||||||
| TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Sarah J. Walsh, Vice President, Federal Government Relations Tax & Pharmaceuticals |
Date | 10/18/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
HR 2112 Fiscal Year 2012 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations
Act - provisions pertaining to Ryan White CARE Act, FDA funding
HR 2017 The Department of Homeland Security Appropriations Act - provisions pertaining to Customs and Border Protection
S 1599 Fiscal Year 2012 Labor - HHS-Education Appropriations -FY 2012 HHS Budget Request; proposal relating to Vaccine
Section 317 program, Ryan White CARE Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S 23, HR 1249 America Invents Act - provisions related to supplemental examination, first inventor to file, best mode, and false
marking
S 27 Preserve Access to Affordable Generics Act - provisions related to patent settlements
HR 1056 Patent Continuing Disclosure Act - provisions related to false patent marking
HR 243, S 515 Patent Lawsuit Reform Act of 2011 - provisions related to false patent marking
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
PL 111-148, PL 111-152 Patient Protection and Affordable Care Act - ACA implementation, Independent Payment Advisory Board (IPAB), comparative effectiveness, health information technology, disease prevention/wellness, sunshine and innovation provisions
HR 1930 Access to Appropriate Immunizations for Veterans Act of 2011- extending VA performance measures to include all federally recommended vaccines
HR 2405Pandemic and All Hazards Preparedness Act - re-authorization; influenza vaccine innovative technologies
S 1002 Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act (SAFE
DOSES) - drug safety
HR 1483The Drug Safety Enhancement Act of 2011- drug safety standards
HR 2182Generating Antibiotic Incentives Now Act of 2011- provisions related to antibiotics and incentives
HR 1930Access to Appropriate Immunizations for Veterans Act of 2011- vaccine access
HR 3202Water Protection and Reinvestment Act - provisions pertaining to pharmaceuticals in the environment
S 3397Secure and Responsible Drug Disposal Act - provisions related to safe drug disposal
S 319 Pharmaceutical Market Access and Drug Safety Act of 2011- provisions related to drug importation
HR 2245Preserving Access to Life-Savings Medicines Act of 2011- provisions related to drug shortages
HR 2939Pharmaceutical Stewardship Act of 2011- provisions related to drug safety
S 1584The Drug Safety and Accountability Act of 2011- provisions related to drug safety
HR 2529, S 1368 Restoring Access to Medication Act - provisions relating to reimbursement of OTC drugs under flexible
spending and health savings accounts
HR 605, S 312 Patients Freedom to Choose Act - provisions relating to reimbursement of OTC drugs under flexible
spending and health savings accounts
ADDENDUM/General Lobbying Issue Area - Federal Food, Drug, and Cosmetic Act (currently unassigned) - section related to FDA and regulation of nicotine replacement therapies
ADDENDUM/General Lobbying Issue Area - Prescription Drug User Fee Act (currently unassigned) - issues related to reauthorization of the Prescription Drug User Fee Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 999 Medicare Prescription Drug Savings and Choice Act of 2011- provisions related to Medicare Part D
HR 2190 Medicare Drug Savings Act of 2011- provisions related to Medicare Part D
HR 2248 Medicare Prescription Drug Price Negotiation Act of 2011 - provision related to Medicare Part D
S 31 Prescription Drug and Health Improvement Act of 2011 - provisions related to Medicare Part D
S 44 Medicare Prescription Drug Price Negotiation Act of 2011- provisions related to Medicare Part D
HR 452 Medicare Decisions Accountability Act - provisions related to the Independent Payment Advisory Board (IPAB)
S 365 Budget Control Act of 2011- deficit reduction issues related to Medicare and Medicaid
S 560 Medicare Prescription Drug Savings and Choice Act of 2011- provisions related to Medicare Part D
S 668 Health Care Bureaucrats Elimination Act - provisions related to the Independent Payment Advisory Board (IPAB)
S 1206 Medicare Prescription Drug Savings Act of 2011- provisions related to Medicare Part D
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Sara |
Weir |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
5 |
|
||||||
| 2 |
|
6 |
|
||||||
| 3 |
|
7 |
|
||||||
| 4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 3 | 5 |
| 2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 5 | 9 |
| 2 | 6 | 10 |
| 3 | 7 | 11 |
| 4 | 8 | 12 |